Science 37 Wins 2023 MedTech Breakthrough Award for "Best Overall Clinical Trial Platform"

Science 37's unified platform that powers the Metasite receives award for outstanding digital health and technology innovation

RESEARCH TRIANGLE PARK, N.C. – May 18, 2023 – Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research industry-leading Metasite™, has been named the winner of the prestigious "Best Overall Clinical Trial Platform" award in the 7th annual MedTech Breakthrough Awards program. Science 37 was chosen by MedTech Breakthrough, an autonomous market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market, in recognition of the Metasite and its transformation of clinical research.

Built on a proprietary unified platform, the Science 37 Metasite, transforms clinical research by enabling patients to participate in trials from the comfort of their homes. The Science 37 unified platform delivers trial orchestration and data capture in a single, end-to-end platform that guides the workflow for patients and study staff, and electronically captures study data. The platform enables eConsent, ePRO, telemedicine, scheduling, and wearable/device integration to deliver clinical trials directly to patients, wherever they are. The result is consistent user journeys, greater compliance, and high-quality data.

“Virtual clinical trials are transforming research by putting patient needs first,” said Troy Bryenton, Chief Technology Officer of Science 37. “The Metasite improves the participant experience by delivering accessible and flexible research options and provides data from a more diverse and real-world sample. Our unified platform makes this possible by delivering the infrastructure that orchestrates the user journey and enables data collection from anywhere.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data, and more. This year’s program attracted more than 4,000 nominations from over 17 different countries throughout the world.

James Johnson, managing director of MedTech Breakthrough, said, “Science 37 is helping to transform clinical research by meeting patients wherever they are, through a decentralized clinical trial model. By offering a complete virtual site solution, Science 37 helps eliminate geographic restrictions, providing convenience with a patient-focused, end-to-end clinical trial experience. Congratulations on being the ‘Best Overall Clinical Trial Platform’”.

Science 37’s unified platform allows for easy-to-follow and standardized processes that deliver greater consistency, compliance, and data accuracy, ensuring reliability for regulators according to GCP standards. From enrollment through to study completion, the patient follows intuitive, app-based processes using their everyday mobile devices or provisioned devices. All data is captured directly into the Science 37 unified platform from all trial stakeholders, including the mobile nurse, who records procedure results as they are performed at the participant’s home. Every step of the patient journey with the Metasite is a high-touch experience that drives study conduct excellence.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com.

About MedTech Breakthrough

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the products offered by Science 37 and the markets in which it operates, and Science 37’s anticipated growth and profitability. These forward-looking statements generally are identified by the words “believe,” “can,” “could”, “seek”, “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the ability to maintain the listing of Science 37’s securities on The Nasdaq Stock Market LLC, (ii) volatility in the price of Science 37’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Science 37 operates, variations in performance across competitors, changes in laws and regulations affecting Science 37’s business, changes in its capital structure, and general economic and financial market conditions, including fluctuations in currency exchange rates, economic instability, and inflationary conditions (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional opportunities, (iv) the risk that Science 37 may never achieve or sustain profitability, (v) the risk that Science 37 will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all, (vi) failure to realize anticipated cost savings, and (vii) risks related to general economic and financial market conditions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Science 37’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 6, 2023 and in the other documents filed by Science 37 from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Science 37 assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Science 37 does not give any assurance that Science 37 will achieve its expectations.

Media Inquiries

Grazia Mohren

Science 37

PR@science37.com

Investor Relations

Steve Halper

LifeSci Advisors

Investors@science37.com

Science 37® Extends Leadership in Decentralized Clinical Trial Market with NextGen SaaS Release to Fully Orchestrate Decentralized Study Conduct

RESEARCH TRIANGLE PARK, N.C., May 10, 2022—Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today introduced a milestone technology release, setting the bar as the most comprehensive, end-to-end platform to fully orchestrate study conduct for decentralized clinical trials (DCTs) and increasingly agile designs that require both remote and on-premise management.

The increase in demand for decentralized and agile clinical research delivery models has required sponsors and CROs to implement numerous point-solution technologies, often resulting in disconnected processes that lead to study delays and threaten data quality.

Unlike many point solutions that enable components of decentralization, the Science 37 technology platform delivers the most comprehensive end-to-end solution in the industry.

Purpose-built to fully orchestrate study conduct across all clinical trial stakeholders, Science 37’s platform coordinates and unifies the stakeholder journey through every clinical trial visit, with exceptional data-capture features to increase compliance and generate the highest-quality data.

Science 37 has strengthened its SaaS platform with advanced configuration features for visit plans and forms with its newest release. The enhanced platform includes an eCOA library, with assessments pre-approved by license holders, and enables automation of the translation process to accelerate global study rollout. Technology platform features are available as full-service, self-service (SaaS), or self-service with support from Science 37.

“There is a fundamental shift toward decentralization, and the industry needs a proven integrated solution,” said David Coman, Chief Executive Officer of Science 37. “Our new platform release delivers this and more, with a front-end that unifies all stakeholder journeys, improves compliance, and generates high-fidelity data, coupled with a backend that delivers speed, flexibility, and scale.”

Science 37's new platform release was developed in collaboration with beta customers, including Boehringer Ingelheim and Thermo Fisher Scientific.

“Boehringer Ingelheim believes in the value of agile clinical trials to develop innovative drugs for patients faster,” said Uli Broedl, Senior Vice President, Head of Global Clinical Development and Operations at Boehringer Ingelheim. “We are excited about our collaboration with Science 37 to develop this highly innovative platform and look forward to leveraging its capabilities in our efforts to advance patient-centric clinical development.”

“Our long-standing partnership with Science 37 has enabled Thermo Fisher Scientific to help establish the direction of Science 37’s new technology release,” said David M. Johnston, Ph.D., Senior Vice President and President, Clinical Research, Thermo Fisher Scientific. “We look to leverage Science 37’s new platform to build and deploy digital solutions ranging from eCOA all the way through to full decentralized clinical trials.”

“With the proliferation of decentralization and the increased use of digital technologies, sponsors face new challenges with integration for various piecemeal solutions,” said Dr. Nimita Limaye, Research VP, Life Sciences R&D Strategy and Technology, IDC. “The industry needs a purpose-built technology platform that can help streamline user experience across all settings of care, ensure better compliance and drive quicker study builds. The latest release of Science 37’s platform helps strengthens these capabilities, and accelerate study timelines”.

To learn more about the Science 37 Technology Platform, visit www.science37.com/technology.

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 l Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:

Drew Bustos

Science 37

pr@science37.com

INVESTOR RELATIONS:

Caroline Paul

Science 37 // Gilmartin

Investors@science37.com

Science 37®’s Operating System Receives ISO Certification for Information Security Management

RESEARCH TRIANGLE PARK, N.C., February 24, 2022 — Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced its Operating System has earned ISO 27001 certification for cybersecurity management as well as the ISO 27701:2019 privacy management certification extension. These two certifications demonstrate Science 37’s continued commitment to embrace quality, robust cybersecurity, privacy and data protection rights.

“As the most complete Operating System for agile clinical trials, cybersecurity and privacy are of utmost importance in our aim to enable universal access,” said Anita Modi, Vice President of Business Transformation at Science 37. “These ISO certifications demonstrate that commitment across our unified technology platform, standardized processes and centralized networks while helping us drive improvements in our Privacy Information Management System.”

ISO 27001 certification is a globally recognized standard for the establishment and certification of an information security management system (ISMS). The standard specifies the requirements for establishing, implementing, operating, monitoring, reviewing, maintaining, and improving a documented ISMS. It sets forth a risk-based approach that focuses on security controls that protect information assets. The ISO 27701:2019 certification extension specifies the requirements for establishing, implementing, operating, monitoring, reviewing, maintaining, and improving a documented privacy information management system. Schellman & Company, LLC, an American National Standard Institute (ANSI) National Accreditation Board (ANAB) and United Kingdom Accreditation Board (UKAB) certified company performed the certifications. The ISMS certifications are publicly available at: https://www.schellman.com/certificate-directory.

“We know with today’s more agile clinical trial designs and decentralized approaches, sponsors, patients, regulators and sites need a dependable and trusted centralized Operating System to effectively execute studies and collect the requisite data at the highest level of quality,” said Ms. Modi. “These certifications are another step in helping show the dedication to cybersecurity and privacy that we all share at Science 37.”

About Science 37

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 (S37®) Agile Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and centralized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, provider communities, and data and devices. Configurable to enable almost any study type, the S37® OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES

Drew Bustos

Science 37

Phone: (984) 377-3737

Email: pr@science37.com

INVESTOR RELATIONS:

Caroline Paul

Gilmartin

Investors@science37.com

Industry-veteran Elisa Cascade Joins Science 37® as Chief Product Officer; Chris Ceppi appointed Chief Technology Officer

Science 37 strengthens its senior executive leadership team, adding key talent to enhance the technology platform underpinning its Operating System.

Science 37, the Operating System for today’s more agile clinical trials, announced Elisa Cascade has joined Science 37 and its senior executive team as Chief Product Officer. Science 37 veteran Chris Ceppi has been appointed to serve as Chief Technology Officer.

Ms. Cascade brings more than 30 years of experience in clinical trial technology, direct-to-patient operations and healthcare strategy, joining Science 37 most recently from ERT where she served as Executive Vice President and Product Line Executive for electronic Clinical Outcomes Assessments (eCOA). Prior to ERT, Ms. Cascade held the role as Chief Product Officer of DrugDev, an IQVIA Company, and Vice President of the Digital Patient Unit at Quintiles. With her extensive clinical trial and technology experience, Ms. Cascade adds additional strategic prowess and decades of execution expertise to Science 37’s Operating System and its ability to accelerate study timelines, minimize patient burden and enroll a more representative patient population.

Science 37 veteran and architect of the Science 37 technology platform, Mr. Ceppi serves in a new leadership role as Chief Technology Officer to provide greater focus on platform and data infrastructure as a service and competitive advantage.

“We’re pleased to have Elisa join Science 37. With her vast industry experience, she brings tremendous acumen and clinical trial technology expertise that will help fuel our mission of enabling universal access to clinical research,” said David Coman, Chief Executive Officer of Science 37. “Elisa has been instrumental in using technology to help transform the industry and enable a better way to serve all clinical trial stakeholders. She will be a great complement to Chris, as CTO, where his technology leadership will be focused on delivering innovation that ensures our Operating System continues to thrive with a solid foundation of technology.”

“As the pioneer of the decentralized clinical trial model, Science 37 has been leading the way to a more patient-centric future for research and driving toward a more adaptable, agile clinical trial,” said Elisa Cascade, Chief Product Officer of Science 37. “It’s a very transformative moment for the company and the industry and I’m looking forward to working together to accelerate timelines and make research more representative by enabling access for patients and providers, anywhere.”

About Science 37:
Science 37, Inc.’s missions it to enable universal access to clinical research—making it easier for patients and providers to participate from anywhere and helping to accelerate the development of treatments that impact patient lives. As a pioneer of decentralized clinical trials, the Science 37 Clinical Trial Operating System (OS) supports today’s more agile clinical research designs with its full stack, end-to-end technology platform and specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators and connected devices. Configurable to enable any study type, the Science 37 OS enables up to 15x faster enrollment, 28% better retention and 3x more diverse patient population with industry-leading workflow orchestration, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:
Drew Bustos
Science 37
Phone: (984) 377-3737
Email: pr@science37.com

INVESTOR RELATIONS:
Caroline Paul
Gilmartin Group
investors@science37.com